1. Home
  2. ANAB vs HIVE Comparison

ANAB vs HIVE Comparison

Compare ANAB & HIVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • HIVE
  • Stock Information
  • Founded
  • ANAB 2005
  • HIVE 1987
  • Country
  • ANAB United States
  • HIVE United States
  • Employees
  • ANAB N/A
  • HIVE N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • HIVE
  • Sector
  • ANAB Health Care
  • HIVE
  • Exchange
  • ANAB Nasdaq
  • HIVE Nasdaq
  • Market Cap
  • ANAB 621.1M
  • HIVE 510.0M
  • IPO Year
  • ANAB 2017
  • HIVE N/A
  • Fundamental
  • Price
  • ANAB $26.94
  • HIVE $2.27
  • Analyst Decision
  • ANAB Buy
  • HIVE Strong Buy
  • Analyst Count
  • ANAB 10
  • HIVE 6
  • Target Price
  • ANAB $49.00
  • HIVE $6.67
  • AVG Volume (30 Days)
  • ANAB 526.3K
  • HIVE 30.3M
  • Earning Date
  • ANAB 08-08-2025
  • HIVE 08-11-2025
  • Dividend Yield
  • ANAB N/A
  • HIVE N/A
  • EPS Growth
  • ANAB N/A
  • HIVE N/A
  • EPS
  • ANAB N/A
  • HIVE N/A
  • Revenue
  • ANAB $111,872,000.00
  • HIVE $115,279,000.00
  • Revenue This Year
  • ANAB N/A
  • HIVE $167.38
  • Revenue Next Year
  • ANAB $24.39
  • HIVE $68.08
  • P/E Ratio
  • ANAB N/A
  • HIVE N/A
  • Revenue Growth
  • ANAB 387.20
  • HIVE 0.71
  • 52 Week Low
  • ANAB $12.21
  • HIVE $1.26
  • 52 Week High
  • ANAB $41.31
  • HIVE $5.54
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 66.30
  • HIVE 55.56
  • Support Level
  • ANAB $25.48
  • HIVE $2.15
  • Resistance Level
  • ANAB $28.50
  • HIVE $2.54
  • Average True Range (ATR)
  • ANAB 1.26
  • HIVE 0.18
  • MACD
  • ANAB 0.02
  • HIVE 0.00
  • Stochastic Oscillator
  • ANAB 70.23
  • HIVE 40.00

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About HIVE HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.

Share on Social Networks: